Renal Transplantation and Raltegravir in HIV-Infected Patients

Inclusion Criteria: * Registration on the French national renal transplantation waiting list (Biomedicines Agency) for a living or cadaveric donor organ * HIV-1-infected patients treated by a three-drug ARV regimen * Immuno-virologic criteria at renal transplantation: undetectable viral load (\<50 copies/mL) and CD4 \>200/mm3 for at least three months on stable ARV * Age \>18 years and \<70 years * Effective contraception for women * Written informed consent * Patient with social security coverage Exclusion Criteria: * Permanent: * Hepatic cirrhosis * Serious psychiatric illness history * EBV or HHV8 lymphoproliferation (lymphoma, systemic Kaposi's sarcoma or multifocal Castleman's disease) * History of PML * HTLV-1 seropositivity * Severe pulmonary or cardiovascular disease with poor short-term vital prognosis * Patient with AgHBs+ * History of cryptosporidiosis * History of fungal infection with multi resistant fungi not likely to respond to oral antifungal therapy * Impossibility or refusal of Raltegravir switch, decision made by doctor or patient * Temporary: * Recent malignancy (between 2 and 5 years according to type) * HPV-related cervical or anal disease: carcinoma in situ, AIN III, CIN III in remission for less than three years * Active infection * HCV infection (PCR-positive)